Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5198-5208

  Tothill, Richard W ^a   Tinker, Anna V ^b   George, Joshy ^a   Brown, Robert ^a   Fox, Stephen B ^a   Lade, Stephen ^d   Johnson, Daryl S ^a   Trivett, Melanie K ^a   Etemadmoghadam, Dariush ^a   Locandro, Bianca ^a   Traficante, Nadia ^a   Fereday, Sian ^a   Hung, Jillian A ^c   Chiew, Yoke Eng ^c   Haviv, Izhak ^a   Gertig, Dorota ^a   Defazio, Anna ^c   Bowtell, David D L ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MUCIN 1; NERVE CELL ADHESION MOLECULE; P CADHERIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; UTERINE TUBE TUMOR; VALIDATION PROCESS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; LASER; MICRODISSECTION; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; TISSUE MICROARRAY;

ADULT; AGED; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LASERS; MICRODISSECTION; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 52649085237     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0196     Document Type: Article

References (50)

1. Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol 2005;16:4-6.
2. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA2001;98:1176-81.
3. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
4. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-86.
5. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65:10602-12.
6. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684-94.
7. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96.
8. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
9. Helleman J, Jansen MP, Span PN, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006;118:1963-71.
10. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-25.
11. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:6300-10.
12. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005;11:2149-55.
13. Skubitz AP, Pambuccian SE, Argenta PA, Skubitz KM. Differential gene expression identifies subgroup of ovarian carcinoma. Transl Res 2006;148:223-48.
14. De Cecco L, Marchionni L, Gariboldi M, et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004;23:8171-83.
15. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
16. Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the GAP statistic. J R Stat Soc Ser B 2001;63:411-23.
17. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
18. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004;2:E108.
19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
20. TusherVG,Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
21. Thomas PD, Kejariwal A, Guo N, et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 2006;34:W645-50.
22. Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Ann Stat 1982;10:1100-20.
23. Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. New York: Springer; 2002.
24. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005;24:1053-65.
25. Sieben NL, Oosting J, Flanagan AM, et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 2005;23:7257-64.
26. Ishioka S, Sagae S, Ito E, Kudo R. Ultrastructural study of benign, low-malignant potential (LMP), and malignant ovarian tumors. Med Electron Microsc 2004;37:37-44.
27. Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of β-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003;63:2913-22.
28. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48:509-17.
29. Dennert G, Anderson CG, Prochazka G. High activity of N-α-benzyloxycarbonyl-L-lysine thiobenzyl ester serine esterase and cytolytic perforin in cloned cell lines is not demonstrable in in-vivo-induced cytotoxic effector cells. Proc Natl Acad Sci U S A 1987;84:5004-8.
30. Loetscher M, Gerber B, Loetscher P, et al. Chemo-kine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996;184:963-9.
31. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intra-tumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
32. SorlieT, Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
33. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
34. Singer G, Kurman RJ, Chang HW, Cho SK, Shih le M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
35. Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004;91:1924-30.
36. Koukourakis Ml, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-80.
37. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436:518-24.
38. Sherman-Baust CA, Weeraratna AT, Rangel LB, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003;3:377-86.
39. Santala M, Simojoki M, Risteli J, Risteli L, Kauppila A. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999;5:4091-6.
40. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9:4792-801.
41. Infante JR. Matsubayashi H, Sato N, et al. Peri-tumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007:25:319-25.
42. Tsujino T, Seshimo I, Yamamoto H, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 2007;13:2082-90.
43. Ueno H. Jones AM, Wilkinson KH, Jass JR, Talbot IC. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut 2004:53:581-6.
44. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
45. ShefferY, Leon O, Pinthus JH, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy- mediated antitu-moral effect. Mol CancerTher 2007;6:570-7.
46. Ahmed N. Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm. J Cell Physiol 2007;213:581-8.
47. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS. Association of E-cadherin and β-catenin immunoexpression with clinicopatho-logic features in primary ovarian carcinomas. Hum Pathol 2004;35:663-9.
48. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
49. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
50. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004;108:173-80.